Display Settings:

Format

Send to:

Choose Destination
Therap Adv Gastroenterol. 2012 May;5(3):189-97. doi: 10.1177/1756283X12437357.

Vasopressin V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

Author information

  • 1Department of Medicine, Section of Gastroenterology and Hepatology, University of Arizona College of Medicine, Tucson, AZ, USA.

Abstract

Hyponatremia is a common problem in patients with advanced cirrhosis. It develops slowly (paralleling the rate of progression of the liver disease) and usually produces no neurological symptoms, although it may exacerbate hepatic encephalopathy. For patients awaiting liver transplantation a low serum sodium level is a strong predictor of pretransplant mortality, independent of the Model for End-stage Liver Disease score (MELD). The pathogenesis of hyponatremia is related to the hemodynamic changes and secondary neurohormonal adaptations that occur in patients with cirrhosis and ascites. The nonosmotic release of arginine vasopressin is the principle cause of the hyponatremia and vasopressin-receptor antagonists are a new class of drugs recently approved for treatment of cirrhotic hyponatremia. In this article we review the safety and efficacy of V2-receptor antagonists in patients with cirrhosis, ascites and hyponatremia.

KEYWORDS:

ascites; cirrhosis; hepatorenal syndrome; hyponatremia; lixivaptan; portal hypertension; satavaptan; tolvaptan; vasopressin

PMID:
22570679
[PubMed]
PMCID:
PMC3342571
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1.
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk